Product Details
| Product Name:
JD-5037 |
CAS No.:
1392116-14-1 |
| Purity:
98.87% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | JD-5037 |
| Description | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
| Animal Research | Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters |
| In vivo | JD5037, when administered at a dosage of 3 mg/kg/day intraperitoneally (i.p.), effectively induces uniform reductions in body weight and mitigates high-fat diet (HFD)-induced hyperglycemia, hepatic injury, and steatosis in obese Magel2-null mice. Likewise, oral administration of JD5037 (3 mg/kg/day, p.o.) significantly diminishes tumor size and eliminates tumors in DEN-treated mice. Moreover, JD5037 reduces anandamide (AEA) levels in hepatocellular carcinoma (HCC) samples from mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (87.33 mM)
|
| Keywords | Cannabinoid Receptor | JD5037 | inhibit | JD-5037 | Inhibitor |
| Inhibitors Related | β-Caryophyllene | CB2 modulator 1 | Pregnenolone | CB1 inverse agonist 1 | Pregnenolone acetate | CB1 antagonist 2 | OMDM-5 | CB2 receptor agonist 2 | AM-1235 | 2,3-Butanediol | Drinabant | AM281 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2615911-12-9
$135.00 / 1mg
-
CAS:2096999-92-5
$197.00 / 1mg
-
CAS:187389-53-3
$40.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1920.00/1mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States